Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone

Diabetes Care

Volumn 20, Issue 2, 1997, Pages 188-193

  Antonucci, Tammy ^a   Whitcomb, Randall ^a   McLain, Richard ^a   Lockwood, Dean ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; FRUCTOSAMINE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; THIAZOLIDINE DERIVATIVE; TROGLITAZONE;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN RESPONSE; LIPID BLOOD LEVEL; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

EID: 0031015407     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.20.2.188     Document Type: Article

References (17)

1. Harris MI: Impaired glucose tolerance in the U.S. population. Diabetes Care 12:464-474, 1989
2. Wingard DL, Scheidt-Nave C, Barrett-Connor EL, McPhillips JB: Prevalence of cardiovascular and renal complications in older adults with normal or impaired glucose tolerance or NIDDM. Diabetes Care 16:1022-1025, 1993
3. Reaven GM: Role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988
4. Kjos SL, Peters RK, Xiang A, Henry OA, Montoro M, Buchanan TA: Predicting future diabetes in Latino women with gestational diabetes. Diabetes 44:586-591, 1995
5. Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Mott DM, Bennett PH: The natural history of impaired glucose tolerance in the Pima Indians. N Engl J Med 319:1500-1506, 1988
6. Knowler WC, Nelson RG, Saad MF, Bennett PH, Pettitt DJ: Determinants of diabetes mellitus in the Pima Indians. Diabetes Care 16 (Suppl. 1):216-227, 1993
7. Yamada T, Aizawa T, Nagasawa Y, Ishihara M, Komatsu M, Komiya I, Shinoda T, Takasu N: Ten-year follow-up of Japanese overweight subjects with impaired glucose tolerance: identification of a diabetes-prone subpopulation. Intern Med 31:877-884, 1992
8. Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H: Characterization of new oral antidiabetic agent CS-045. Diabetes 37:1549-1558, 1988
9. Ciaraldi TP, Gilmore A, Olefsky JM, Gold-berg M, Heidenreich KA: In vitro studies on the action of CS-045: a new antidiabetic agent. Metabolism 39:1056-1062, 1990
10. Iwamoto Y, Kuzuya T, Matsuda A, Awata T, Kumakura S, Inooka G, Shiraishi I: Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care 14:1083-1086, 1991
11. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM: Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 15:193-203, 1992
12. Valiquett TR, Balagtas CC, Whitcomb RW, Lockwood DH: Troglitazone dose-response study in patients with noninsulin dependent diabetes (Abstract). Clin Res 42:400A, 1994
13. Ritchie A, Norris R, Antonucci T: Practical experience recruiting subjects with impaired glucose tolerance for clinical trials (Abstract). Diabetes 43 (Suppl. 1):215A, 1994
14. Glantz SA: How to test for differences between groups. Primer of Biostatistics. 2nd ed. New York, McGraw-Hill, 1987
15. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J: Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 331:1188-1193, 1994
16. World Health Organization (WHO): Impaired glucose tolerance and diabetes: WHO criteria. Br Med J 281:1512-1513, 1980
17. National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28:1039-1057, 1979